CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
- Thursday, June 11, 2020, 7:22
- PR Newswire
- Add a comment
HOUSTON, June 11, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the U….
About the Author
admin has written 21043 stories on this site.